D Groheux

Summary

Country: France

Publications

  1. ncbi request reprint [Interests and perspectives of PET-CT for breast cancer: review of the literature]
    David Groheux
    Service de médecine nucléaire et centre TEP, Hopital Saint Louis, Paris
    Bull Cancer 94:658-68. 2007
  2. doi request reprint Effect of variation in relaxation parameter value on LOR-RAMLA reconstruction of 18F-FDG PET studies
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, University of Paris VII, Paris, France
    Nucl Med Commun 30:926-33. 2009
  3. doi request reprint Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy
    David Groheux
    Department of Nuclear Medicine, St Louis Hospital, Paris, France
    Cancer 119:1960-8. 2013
  4. doi request reprint Performance of FDG PET/CT in the clinical management of breast cancer
    David Groheux
    Department of Nuclear Medicine and Department of Medical Oncology, Breast Diseases Unit, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Radiology 266:388-405. 2013
  5. doi request reprint 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France
    J Nucl Med 54:5-11. 2013
  6. pmc Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer
    David Groheux
    Service de Medecine Nucleaire, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, 1 Ave Claude Vellefaux, 75475 Paris Cedex 10, France
    J Natl Cancer Inst 104:1879-87. 2012
  7. doi request reprint Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France
    J Nucl Med 53:249-54. 2012
  8. doi request reprint The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France
    J Nucl Med 52:1526-34. 2011
  9. doi request reprint Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Eur J Nucl Med Mol Imaging 38:426-35. 2011
  10. ncbi request reprint [PET-CT for evaluation of the solitary pulmonary nodule: an update]
    D Groheux
    Service de Medecine Nucleaire, Pôle Imagerie Cancérologie PIC, Hopital Saint Louis, Assistance Publique des Hopitaux de Paris, Paris, France
    Rev Mal Respir 26:1041-55. 2009

Detail Information

Publications15

  1. ncbi request reprint [Interests and perspectives of PET-CT for breast cancer: review of the literature]
    David Groheux
    Service de médecine nucléaire et centre TEP, Hopital Saint Louis, Paris
    Bull Cancer 94:658-68. 2007
    ..Nevertheless, the data of the literature appear insufficient to recommend it in current practice. It is the same way for the prognostic interest...
  2. doi request reprint Effect of variation in relaxation parameter value on LOR-RAMLA reconstruction of 18F-FDG PET studies
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, University of Paris VII, Paris, France
    Nucl Med Commun 30:926-33. 2009
    ....
  3. doi request reprint Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy
    David Groheux
    Department of Nuclear Medicine, St Louis Hospital, Paris, France
    Cancer 119:1960-8. 2013
    ....
  4. doi request reprint Performance of FDG PET/CT in the clinical management of breast cancer
    David Groheux
    Department of Nuclear Medicine and Department of Medical Oncology, Breast Diseases Unit, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Radiology 266:388-405. 2013
    ....
  5. doi request reprint 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France
    J Nucl Med 54:5-11. 2013
    ..We prospectively investigated the impact of (18)F-FDG PET/CT at initial staging in this clinical setting and compared PET/CT performance with that of conventional distant work-up...
  6. pmc Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer
    David Groheux
    Service de Medecine Nucleaire, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, 1 Ave Claude Vellefaux, 75475 Paris Cedex 10, France
    J Natl Cancer Inst 104:1879-87. 2012
    ..This study prospectively evaluated the yield of fluorodeoxyglucose positron emission tomography/computed tomography ((18)FDG-PET-CT) in patients with clinical stages II and III breast cancer and the impact of PET-CT results on prognosis...
  7. doi request reprint Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France
    J Nucl Med 53:249-54. 2012
    ..Triple-negative breast cancer, an aggressive subtype, represents 15% of invasive breast tumors. This prospective study investigated whether early changes in (18)F-FDG tumor uptake during neoadjuvant chemotherapy (NAC) can predict outcomes...
  8. doi request reprint The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France
    J Nucl Med 52:1526-34. 2011
    ..The purpose of this study was to prospectively evaluate the role of (18)F-FDG PET/CT in patients with stage IIA, IIB, or IIIA breast cancer...
  9. doi request reprint Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Eur J Nucl Med Mol Imaging 38:426-35. 2011
    ..Only women with tumours larger than 20 mm (T2-T4) were included in order to minimize bias of partial volume effect...
  10. ncbi request reprint [PET-CT for evaluation of the solitary pulmonary nodule: an update]
    D Groheux
    Service de Medecine Nucleaire, Pôle Imagerie Cancérologie PIC, Hopital Saint Louis, Assistance Publique des Hopitaux de Paris, Paris, France
    Rev Mal Respir 26:1041-55. 2009
    ..Positron emission tomography (PET) with 18F-FDG has become an important tool for the characterization of solitary pulmonary nodules (SPN)...
  11. doi request reprint [PET/CT in breast cancer: an update]
    D Groheux
    Service de Medecine Nucleaire, Pôle Imagerie Cancérologie PIC, Hopital Saint Louis, Assistance Publique des Hopitaux de Paris, 1, avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Bull Cancer 96:1053-70. 2009
    ..18FDG-PET/CT could thus become an unavoidable modality to answer various clinical situations...
  12. doi request reprint [Advantages of PET-CT in the work-up of cervical cancer]
    D Groheux
    Service de Medecine Nucleaire, pôle PIC, Hopital Saint Louis, Assistance publique des Hôpitaux de Paris APHP, 1 avenue Claude Vellefaux, Paris Cedex 10, France
    Bull Cancer 96:199-211. 2009
    ..PET is useful to evaluate therapy, but its exact role in this issue remains to be further refined. Finally, PET-CT can document early recurrence of disease...
  13. doi request reprint Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer
    David Groheux
    Department of Nuclear Medicine, Breast Diseases Unit, Saint Louis Hospital, Paris, France
    Int J Radiat Oncol Biol Phys 71:695-704. 2008
    ..To investigate the potential effect of using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in the initial assessment of patients with clinical Stage II or III breast cancer...
  14. doi request reprint [Sentinel node biopsy in breast cancer]
    E Hindie
    Service de Medecine Nucleaire, Hopital Saint Louis, Assistance Publique des Hopitaux de Paris, 1, avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Bull Cancer 96:713-25. 2009
    ..can benefit from the sentinel node technique? 2) What is the optimal methodology? 3) What is the prognostic significance of micrometastases and of isolated tumour cells? 4) What attention should be given to extra-axillary drainage?..
  15. pmc HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment
    D Groheux
    1 Nuclear Medicine, Saint Louis Hospital, 1 avenue Claude Vellefaux, Paris 75475, France 2 B2T, Doctoral School, IUH, University of Paris VII, Paris, France
    Br J Cancer 109:1157-64. 2013
    ..Because many innovative therapeutic strategies are now available (e.g., addition of a second HER2-directed therapy or an antiangiogenic), early prediction of poor response is critical. ..